TY - JOUR
T1 - Long-acting slow effective release antiretroviral therapy
AU - Edagwa, Benson
AU - McMillan, Jo Ellyn
AU - Sillman, Brady
AU - Gendelman, Howard E.
N1 - Publisher Copyright:
© 2017 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2017/11/2
Y1 - 2017/11/2
N2 - Introduction: Advances in long-acting antiretroviral therapy (ART) can revolutionize current HIV/AIDS treatments. We coined the term ‘long-acting slow effective release ART’ (LASER ART) to highlight the required formulation properties of slow drug dissolution, poor water-solubility, bioavailability, little-to-no off-target toxicities and improved regimen adherence. Drug carrier technologies characterized by high antiretroviral drug (ARV) payloads in a single carrier improve the pharmacokinetic and pharmacodynamic profiles. The surface modifications of ARV carriers target monocyte-macrophages and facilitate drug transport across physiological barriers and to virus-susceptible CD4 + T cells. Areas covered: The review highlights developments of reservoir-targeted LASER ART for improved therapeutic outcomes. Such nanoART delivery platforms include decorated multifunctional nano- and micro-particles, prodrugs and polymer conjugates. Therapeutic strategies such as gene-editing technologies boost ART effectiveness. Expert opinion: The persistence of HIV-1 in lymphoid, gut and nervous system reservoirs poses a challenge to viral eradication. Emerging slow-release drug carriers can target intracellular pathogens, activate antiviral immunity, promote genome editing, sustain drug depots and combine therapeutics with image contrast agents, and can meet unmet clinical needs for HIV-infected patients. Such efforts will bring the medicines to reservoir sites and accelerate viral clearance.
AB - Introduction: Advances in long-acting antiretroviral therapy (ART) can revolutionize current HIV/AIDS treatments. We coined the term ‘long-acting slow effective release ART’ (LASER ART) to highlight the required formulation properties of slow drug dissolution, poor water-solubility, bioavailability, little-to-no off-target toxicities and improved regimen adherence. Drug carrier technologies characterized by high antiretroviral drug (ARV) payloads in a single carrier improve the pharmacokinetic and pharmacodynamic profiles. The surface modifications of ARV carriers target monocyte-macrophages and facilitate drug transport across physiological barriers and to virus-susceptible CD4 + T cells. Areas covered: The review highlights developments of reservoir-targeted LASER ART for improved therapeutic outcomes. Such nanoART delivery platforms include decorated multifunctional nano- and micro-particles, prodrugs and polymer conjugates. Therapeutic strategies such as gene-editing technologies boost ART effectiveness. Expert opinion: The persistence of HIV-1 in lymphoid, gut and nervous system reservoirs poses a challenge to viral eradication. Emerging slow-release drug carriers can target intracellular pathogens, activate antiviral immunity, promote genome editing, sustain drug depots and combine therapeutics with image contrast agents, and can meet unmet clinical needs for HIV-infected patients. Such efforts will bring the medicines to reservoir sites and accelerate viral clearance.
KW - Antiretroviral therapy
KW - HIV-1 proviral excision
KW - anti-inflammatory activities
KW - long-acting slow effective release
KW - nanoformulated ART
KW - neuroprotection
KW - prodrugs
KW - targeted drug delivery
KW - theranostics
KW - viral reservoirs
UR - http://www.scopus.com/inward/record.url?scp=85030869966&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030869966&partnerID=8YFLogxK
U2 - 10.1080/17425247.2017.1288212
DO - 10.1080/17425247.2017.1288212
M3 - Review article
C2 - 28128004
AN - SCOPUS:85030869966
SN - 1742-5247
VL - 14
SP - 1281
EP - 1291
JO - Expert Opinion on Drug Delivery
JF - Expert Opinion on Drug Delivery
IS - 11
ER -